LTP·01learntopeptide
Cognitive & neuroPeptideEvidence B4 cited

Cerebrolysin

Porcine Brain Peptide Complex

aka FPF-1070 · brain-derived peptide mixture · porcine brain peptides

A porcine-derived neuropeptide complex researched for neuroprotection, cognitive recovery, and stroke rehabilitation.

Half-life
30 min
clinical
Tmax
1 h
Route
Subcutaneous injection

Sequence

Read this before quoting the sequence
NOT a single defined peptide and has no sequence. Cerebrolysin is a porcine brain-derived preparation produced by standardised enzymatic breakdown of purified brain proteins, yielding a mixture of low-molecular-weight neuropeptides and free amino acids. It is supplied as an aqueous concentrate at 215.2 mg/mL. Because it is a mixture, no molecular formula, molecular weight, CAS number or PubChem CID exists for it, and PubChem returns no record.
Source ↗

Mechanism of action

Cerebrolysin is thought to mimic the action of endogenous neurotrophic factors, promoting neuronal survival and differentiation. It enhances synaptic plasticity and supports neurogenesis by activating signaling pathways such as MAPK/ERK and PI3K/Akt. Additionally, it reduces oxidative stress and inflammation in neural tissues, providing neuroprotection.

What the evidence actually shows

Grade B

Several human trials have been conducted, primarily in Eastern Europe and Asia, showing improvements in cognitive function and recovery post-stroke. However, the studies often have small sample sizes and methodological limitations, necessitating further large-scale, high-quality trials.

Regulatory status

Status
A registered medicine in a number of countries (the manufacturer, EVER Pharma, is based in Austria with production in Germany), but explicitly NOT registered with the US FDA. The manufacturer states: 'Cerebrolysin is not registered with the U.S. Food and Drug Administration (FDA) and is not approved for sale or distribution in the United States.' It has no UK marketing authorisation.
Approved as
Solution for injection, 215.2 mg/mL (registered nationally in certain countries; the specific country list was not verifiable from a regulatory source in this pass)
Clinical stage
Marketed in some countries; large randomised trials published in acute ischaemic stroke (CASTA, primary endpoint neutral) and meta-analysed in Alzheimer's disease.
UK
research_compound

In the UK, Cerebrolysin is not licensed for medical use and is considered a research compound.

Source ↗

Pharmacokinetics

Half-life
30 min
Tmax
1 h
Absorption
iv
Elimination
renal
Washout
1 days
Low-confidence pharmacokinetics
These figures are recorded as clinical rather than measured in a published PK study. Treat them as an order of magnitude. Anything downstream of them — accumulation, steady state, washout — inherits that uncertainty.

Dosing — what backs each figure

Cerebrolysin is the only compound in this batch with real approved labelling. It is a porcine brain-derived peptide concentrate (215.2 mg/mL) licensed in Austria, Russia, China and around 50 other countries — but not by the FDA or EMA — and given as an intravenous infusion in defined courses: 20-50 mL/day for 10-21 days in stroke, 20-50 mL/day for 7-30 days in traumatic brain injury, and 10-30 mL/day five days a week for 4 weeks, 2-4 cycles a year, in dementia. It is a hospital-administered infusion, not a self-injected peptide, and the evidence base for its efficacy remains contested (Cochrane reviews find no convincing benefit in acute stroke).

ClinicalApproved labelling or a published human trial

Handling and storage

Lyophilized
No compound-specific data documented
Reconstituted
No compound-specific data documented
Solvent
None - supplied as a ready-to-use aqueous solution for injection at 215.2 mg/mL

Cerebrolysin is a nationally registered medicine in several countries but is not licensed in the UK, EU-centrally or the US, and no publicly accessible SmPC was retrievable in this pass, so no storage temperature or duration is recorded here. It is supplied as a ready-to-use solution in ampoules, not as a lyophilised powder, so lyophilised-stability framing does not apply.

Source ↗
→ Reconstitution walkthrough→ Reconstitution calculator

Safety

Commonly reported
  • ·Headache
  • ·Dizziness
  • ·Nausea
Rarely reported
  • ·Seizures
  • ·"Allergic reactions"
Contraindications
  • ·Severe renal impairment
  • ·Known hypersensitivity to Cerebrolysin
Drug interactions
  • ·May enhance the effects of antidepressants due to overlapping pathways

Reported combinations

Reported as synergistic
  • ·Acetyl-L-carnitine
Reported as antagonistic
  • ·High-dose corticosteroids

Combination claims in this dataset are largely unsourced and should be treated as folk knowledge until a citation appears beside them.

References (4)

Data provenance

Chemistry and citations on this page were checked against primary sources on 2026-08-14. Values that could not be verified were left blank rather than filled with a plausible guess.

Could not verify
sequence, molecularFormula, molecularWeight, casNumber, pubchemCid, storage.lyophilized, storage.reconstituted, storage.lightSensitive, regulatory.wada

Research use only
This profile is educational reference material. It is not medical advice, not a prescription, and not an endorsement of self-administration. Compounds discussed here are research chemicals and most are not approved for human therapeutic use.

Related in Cognitive & neuro

ARA-290
An 11-amino acid peptide derived from erythropoietin (EPO) that activates the innate repair receptor (IRR) without stimulating erythropoiesis. Provides neuroprotection, anti-inflammatory, and tissue repair effects.
CAQK
Brain-injury-homing tetrapeptide targeting chondroitin sulfate proteoglycans at injury sites.
Dihexa
A small peptide that mimics BDNF, with research noting potent neurogenesis and synapse formation in animal models.